4 research outputs found
Primary series COVID-19 vaccine effectiveness among healthcare workers in Albania, February–December 2021
Background: Healthcare workers have experienced high rates of morbidity and mortality from coronavirus disease
2019 (COVID-19).
Methods: A prospective cohort study was conducted in three Albanian hospitals between 19 February and 14
December 2021. All participants underwent polymerase chain reaction (PCR) and serological testing at enrolment,
regular serology throughout, and PCR testing when symptomatic.
Vaccine effectiveness (VE) against COVID-19 and against all severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) infections (symptomatic or asymptomatic) was estimated. VE was estimated using a Cox regression
model, with vaccination status as a time-varying variable.
Findings: In total, 1504 HCWs were enrolled in this study; 70% had evidence of prior SARS-CoV-2 infection.
VE was 65.1% [95% confidence interval (CI) 37.7–80.5] against COVID-19, 58.2% (95% CI 15.7–79.3) among
participants without prior SARS-CoV-2 infection, and 73.6% (95% CI 24.3–90.8) among participants with prior
SARS-CoV-2 infection. For BNT162b2 alone, VE was 69.5% (95% CI 44.5–83.2). During the period when the
Delta variant was predominant, VE was 67.1% (95% CI 38.3–82.5). VE against SARS-CoV-2 infection for the full
study period was 36.9% (95% CI 15.8–52.7).
Interpretation: This study found moderate primary series VE against COVID-19 among healthcare workers in
Albania. These results support the continued promotion of COVID-19 vaccination in Albania, and highlight the
benefits of vaccination in populations with high levels of prior infection
Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018–2019
Network authors: Portugal - Raquel Guiomar, Pedro Pechirra, National Influenza
Reference Laboratory, Infectious Diseases Department, National
Institute of Health Dr. Ricardo Jorge, Lisbon, PortugalBackground: The 2018/2019 influenza season in the WHO European Region was dominated by influenza A (H1N1)pdm09 and (H3N2) viruses, with very few influenza B viruses detected.
Methods: Countries in the European Region reported virus characterization data to The European Surveillance System for weeks 40/2018 to 20/2019. These virus antigenic and genetic characterization and haemagglutinin (HA) sequence data were analysed to describe and assess circulating viruses relative to the 2018/2019 vaccine virus components for the northern hemisphere.
Results: Thirty countries reported 4776 viruses characterized genetically and 3311 viruses antigenically. All genetically characterized A(H1N1)pdm09 viruses fell in subclade 6B.1A, of which 90% carried the amino acid substitution S183P in the HA gene. Antigenic data indicated that circulating A(H1N1)pdm09 viruses were similar to the 2018/2019 vaccine virus. Genetic data showed that A(H3N2) viruses mostly fell in clade 3C.2a (75%) and 90% of which were subclade 3C.2a1b. A lower proportion fell in clade 3C.3a (23%) and were antigenically distinct from the vaccine virus. All B/Victoria viruses belonged to clade 1A; 30% carried a double amino acid deletion in HA and were genetically and antigenically similar to the vaccine virus component, while 55% carried a triple amino acid deletion or no deletion in HA; these were antigenically distinct from each other and from the vaccine component. All B/Yamagata viruses belonged to clade 3 and were antigenically similar to the virus component in the quadrivalent vaccine for 2018/2019.
Conclusions: A simultaneous circulation of genetically and antigenically diverse A(H3N2) and B/Victoria viruses was observed and represented a challenge to vaccine strain selection.Highlights: Co-circulation of different clades/subclades of influenza A viruses in 2018/2019 in the Region; Most circulating A(H1N1)pdm09 viruses (6B.1A) carried S183P in hemagglutinin; Genetically heterogeneous A(H3N2) viruses, with co-circulation of clades 3C.2a and 3C.3a; Antigenically distinct A(H3N2) clade 3C.3a viruses were increasingly detected until 02/2019 and then decreased; Co-circulation of genetically and antigenically diverse A(H3N2) strains challenges vaccine strain selection.info:eu-repo/semantics/publishedVersio